Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients.
OBJECTIVE
To analyze our results with mycophenolate mofetil (MMF) in stable liver transplantation (LT) patients presenting with adverse events (AE) related to prolonged use of calcineurin inhibitors (CNI).


METHODS
Conversion to MMF was performed in 56 out of 323 LT patients from 91-02: 24 (43%) were converted to MMF in monotherapy and 32 (57%) to MMF+low doses of CNI. The indication for conversion was chronic renal insufficiency (CRI) in all patients. The mean time between AE and conversion was 38.7+/-30 months (r: 2-101 m). Post-conversion follow-up was 39+/-20 months (r: 3-72 m).


RESULTS
The calculated creatinine clearance (Crauckoft), improved significantly in all patients. In those converted to MMF, improvement was seen during the first 18 months for urea and during the first 6 months for creatinine. In patients converted to MMF+CNI, improvement was maintained throughout the conversion period for both urea and creatinine. Eleven (19.6%) patients underwent acute rejection (2 severe episodes in the MMF group and 1 death). Hypertension was present in 31 patients but only improved in 4 (7%). Dyslipemia was found in 12 and improved in 4 (7%). DM was present in 14 and improved in 1 (2%).


CONCLUSIONS
Conversion to MMF in monotherapy is useful in stable LT patients with CRI due to CNI, although this result is offset by more severe rejections. Therefore, for AE secondary to CNI, we propose an early conversion to MMF+low doses of CNI as a first step. If liver function remains stable and AEs persist or progress, conversion to MMF in monotherapy is recommended, as a second step, with close monitoring of the patient.
Bilbao
Itxarone
I
Liver Transplantation Unit of the Department of General Surgery, Hospital Vall Hebrón, Universidad Autónoma Barcelona, Spain. ibilbao@vhebron.net <ibilbao@vhebron.net>
Castells
Luis
L
Rojas
Luis
L
Cancino
Jorge
J
Dopazo
Cristina
C
Castro
Ernest
E
Pou
Leonor
L
Andino
Ricardo
R
Margarit
Carlos
C
D000368:Aged; D065095:Calcineurin Inhibitors; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007668:Kidney / Q000503:physiopathology; D008099:Liver / Q000187:drug effects / Q000503:physiopathology; D016031:Liver Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011183:Postoperative Complications; D051436:Renal Insufficiency, Chronic / Q000097:blood / Q000139:chemically induced; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D014508:Urea / Q000097:blood
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D014508:Urea; D003404:Creatinine; D009173:Mycophenolic Acid